Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/pTRF

Physiological Reports

Volumn 1, Issue 1, 2013, Pages

  Swärd, Karl ^a   Sadegh, Mardjaneh K ^a   Mori, Michiko ^a   Erjefält, Jonas S ^a   Rippe, Catarina ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bmp4; Caveolin; Foxc2; Lpin1; Nitric oxide; Plau

Indexed keywords

NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARG1 GENE; ARTICLE; CONTROLLED STUDY; DDAH1 GENE; DOWN REGULATION; GENE; GENE EXPRESSION; HEART RIGHT VENTRICLE PRESSURE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG STRUCTURE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SCANNING TRANSMISSION ELECTRON MICROSCOPY; TISSUE PREPARATION; UPREGULATION; WESTERN BLOTTING;

EID: 85009080421     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.8     Document Type: Article

References (35)

1. Albinsson, S., Y. Shakirova, A. Rippe, M. Baumgarten, B. I. Rosengren, C. Rippe, et al. 2007. Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1222–R1231.
2. Aravamudan, B., S. K. Vanoosten, L. W. Meuchel, P. Vohra, M. Thompson, G. C. Sieck, et al. 2012. Caveolin-1 knockout mice exhibit airway hyperreactivity. Am. J. Physiol. Lung Cell. Mol. Physiol. 303: L669–L681.
3. Arrigoni, F. I., P. Vallance, S. G. Haworth, and J. M. Leiper. 2003. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107: 1195–1201.
4. Austin, E. D., L. Ma, C. Leduc, E. Berman Rosenzweig, A. Borczuk, J. A. Phillips III, et al. 2012. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ. Cardiovasc. Genet. 5: 336–343.
5. Badesch, D. B., H. C. Champion, M. A. Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, et al. 2009. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54: S55–S66.
6. Davalos, A., C. Fernandez-Hernando, G. Sowa, B. Derakhshan, M. I. Lin, J. Y. Lee, et al. 2010. Quantitative proteomics of caveolin-1-regulated proteins: characterization of polymerase I and transcript release factor/CAVIN-1 IN endothelial cells. Mol. Cell. Proteomics 9: 2109–2124.
7. Drab, M., P. Verkade, M. Elger, M. Kasper, M. Lohn, B. Lauterbach, et al. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449–2452.
8. Gorenflo, M., C. Zheng, E. Werle, W. Fiehn, and H. E. Ulmer. 2001. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J. Cardiovasc. Pharmacol. 37: 489–492.
9. Heagerty, A. M., C. Aalkjaer, S. J. Bund, N. Korsgaard, and M. J. Mulvany. 1993. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 21: 391–397.
10. Hill, M. M., M. Bastiani, R. Luetterforst, M. Kirkham, A. Kirkham, S. J. Nixon, et al. 2008. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 132: 113–124.
11. Hsu, L. L., H. C. Champion, S. A. Campbell-Lee, T. J. Bivalacqua, E. A. Manci, B. A. Diwan, et al. 2007. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109: 3088–3098.
12. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, et al. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.
13. Jasmin, J. F., I. Mercier, J. Dupuis, H. B. Tanowitz, and M. P. Lisanti. 2006. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 114: 912–920.
14. Karbalaei, M. S., C. Rippe, S. Albinsson, M. Ekman, A. Mansten, B. Uvelius, et al. 2012. Impaired contractility and detrusor hypertrophy in cavin-1-deficient mice. Eur. J. Pharmacol. 689: 179–185.
15. Kielstein, J. T., S. M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, et al. 2005. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 25: 1414–1418.
16. Leiper, J., M. Nandi, B. Torondel, J. Murray-Rust, M. Malaki, B. O’hara, et al. 2007. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13: 198–203.
17. Liu, L., D. Brown, M. McKee, N. K. Lebrasseur, D. Yang, K. H. Albrecht, et al. 2008. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 8: 310–317.
18. Machado, R. D., O. Eickelberg, C. G. Elliott, M. W. Geraci, M. Hanaoka, J. E. Loyd, et al. 2009. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54: S32–S42.
19. Mandegar, M., Y. C. Fung, W. Huang, C. V. Remillard, L. J. Rubin, and J. X. Yuan. 2004. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc. Res. 68: 75–103.
20. Maniatis, N. A., V. Shinin, D. E. Schraufnagel, S. Okada, S. M. Vogel, A. B. Malik, et al. 2008. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1_/_ mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L865–L873.
21. Meyer, C., Y. Liu, and S. Dooley. 2013. Caveolin and TGFbeta entanglements. J. Cell. Physiol. [Epub ahead of print].
22. Millatt, L. J., G. S. Whitley, D. Li, J. M. Leiper, H. M. Siragy, R. M. Carey, et al. 2003. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.
23. Murata, T., M. I. Lin, Y. Huang, J. Yu, P. M. Bauer, F. J. Giordano, et al. 2007. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J. Exp. Med. 204: 2373–2382.
24. Nohe, A., E. Keating, T. M. Underhill, P. Knaus, and N. O. Petersen. 2005. Dynamics and interaction of caveolin-1 isoforms with BMP-receptors. J. Cell Sci. 118: 643–650.
25. Pernow, J., and C. Jung. 2013. Arginase as a potential target in treatment of cardiovascular disease-reversal of arginine steal? Cardiovasc. Res. 98: 334–343.
26. Rahman, A., and K. Sward. 2009. The role of caveolin-1 in cardiovascular regulation. Acta Physiol. 195: 231–245.
27. Razani, B., J. A. Engelman, X. B. Wang, W. Schubert, X. L. Zhang, C. B. Marks, et al. 2001. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276: 38121–38138.
28. Rosengren, B. I., A. Rippe, C. Rippe, D. Venturoli, K. Sward, and B. Rippe. 2006. Transvascular protein transport in mice lacking endothelial caveolae. Am. J. Physiol. Heart Circ. Physiol. 291: H1371–H1377.
29. Sadegh, M. K., M. Ekman, C. Rippe, F. Sundler, N. Wierup, M. Mori, et al. 2011. Biomechanical properties and innervation of the female caveolin-1-deficient detrusor. Br. J. Pharmacol. 162: 1156–1170.
30. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98: 5116–5121.
31. Wunderlich, C., A. Schmeisser, C. Heerwagen, B. Ebner, K. Schober, R. C. Braun-Dullaeus, et al. 2008a. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm. Pharmacol. Ther. 21: 507–515.
32. Wunderlich, C., K. Schober, A. Schmeisser, C. Heerwagen, A. K. Tausche, N. Steinbronn, et al. 2008b. The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J. Mol. Cell. Cardiol. 44: 938–947.
33. Yu, P. B., D. Y. Deng, H. Beppu, C. C. Hong, C. Lai, S. A. Hoyng, et al. 2008. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J. Biol. Chem. 283: 3877–3888.
34. Zhao, Y. Y., Y. Liu, R. V. Stan, L. Fan, Y. Gu, N. Dalton, et al. 2002. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl. Acad. Sci. USA 99: 11375–11380.
35. Zhao, Y. Y., Y. D. Zhao, M. K. Mirza, J. H. Huang, H. H. Potula, S. M. Vogel, et al. 2009. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J. Clin. Investig. 119: 2009–2018.